Cargando…

Predictors of toxicity for metastatic melanoma patients treated with ipilimumab

Detalles Bibliográficos
Autores principales:	Valpione, Sara, Pasquali, Sandro, Campana, Luca, Mocellin, Simone, Piccin, Luisa, Pigozzo, Jacopo, Chiarion-Sileni, Vanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649556/ http://dx.doi.org/10.1186/2051-1426-3-S2-P247

Ejemplares similares

Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
por: Valpione, Sara, et al.
Publicado: (2018)

Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib
por: Valpione, Sara, et al.
Publicado: (2015)

Development and External Validation of a Prognostic Nomogram for Metastatic Uveal Melanoma
por: Valpione, Sara, et al.
Publicado: (2015)

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
por: Queirolo, Paola, et al.
Publicado: (2014)

RIPK3 and AXL Expression Study in Primary Cutaneous Melanoma Unmasks AXL as Predictor of Sentinel Node Metastasis: A Pilot Study
por: Nicolè, Lorenzo, et al.
Publicado: (2021)

Investigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach
por: Catoni, Cristina, et al.
Publicado: (2022)

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
por: Ascierto, Paolo Antonio, et al.
Publicado: (2013)

The immune cell landscape of metastatic uveal melanoma correlates with overall survival
por: Tosi, Anna, et al.
Publicado: (2021)

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme
por: Chiarion Sileni, Vanna, et al.
Publicado: (2014)

A gene expression signature associated with survival in metastatic melanoma
por: Mandruzzato, Susanna, et al.
Publicado: (2006)

Per- and polyfluoroalkyl substances (PFAS) exposure in melanoma patients: a retrospective study on prognosis and histological features
por: Del Fiore, Paolo, et al.
Publicado: (2022)

Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab
por: Koguchi, Yoshinobu, et al.
Publicado: (2015)

Optimization of resources by drug management: A multicentred web-administered study on the use of ipilimumab in Italy
por: Damuzzo, V, et al.
Publicado: (2018)

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy
por: Chiarion-Sileni, V, et al.
Publicado: (2014)

Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial
por: Guida, Michele, et al.
Publicado: (2003)

Molecular Modeling Unveils the Effective Interaction of B-RAF Inhibitors with Rare B-RAF Insertion Variants
por: Scaini, Maria Chiara, et al.
Publicado: (2023)

Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma
por: Russo, Irene, et al.
Publicado: (2018)

Melanoma M (Zero): Diagnosis and Therapy
por: Rastrelli, Marco, et al.
Publicado: (2013)

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
por: Ascierto, Paolo A, et al.
Publicado: (2014)

T cell receptor diversity evaluation to predict patient response to Ipilimumab in metastatic melanoma
por: Postow, Michael, et al.
Publicado: (2014)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
por: Stucci, Stefania, et al.
Publicado: (2015)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
por: Jeter, Joanne M., et al.
Publicado: (2012)

The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma
por: Daly, Louise E, et al.
Publicado: (2017)

Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
por: Stoff, Ronen, et al.
Publicado: (2022)

The cost of unresectable stage III or stage IV melanoma in Italy
por: Maio, Michele, et al.
Publicado: (2012)

Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy
por: Prithviraj, Prashanth, et al.
Publicado: (2015)

Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme
por: Altomonte, Maresa, et al.
Publicado: (2013)

Ipilimumab cystic hypophysitis mimicking metastatic melanoma
por: Wallace, John, et al.
Publicado: (2018)

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

The full blood count as a biomarker of outcome and toxicity in ipilimumab‐treated cutaneous metastatic melanoma
por: Khoja, Leila, et al.
Publicado: (2016)

Profile of ipilimumab and its role in the treatment of metastatic melanoma
por: Patel, Sapna P, et al.
Publicado: (2011)

Ipilimumab in the treatment of metastatic melanoma: management of adverse events
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014)

Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma
por: Formozo, A. A., et al.
Publicado: (2021)

Melanoma of Unknown Primary: Evaluation of the Characteristics, Treatment Strategies, Prognostic Factors in a Monocentric Retrospective Study
por: Del Fiore, Paolo, et al.
Publicado: (2021)

No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study
por: Guida, Michele, et al.
Publicado: (2021)

Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study
por: Maccalli, Cristina, et al.
Publicado: (2013)

Corrigendum: Melanoma of Unknown Primary: Evaluation of the Characteristics, Treatment Strategies, Prognostic Factors in a Monocentric Retrospective Study
por: Del Fiore, Paolo, et al.
Publicado: (2021)

Altitude Effect on Cutaneous Melanoma Epidemiology in the Veneto Region (Northern Italy): A Pilot Study
por: Del Fiore, Paolo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0g6gsabe7u73709liju3bm3c6g